Phase 3

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter